BIVALIRUDIN USE AND SHORT TERM OUTCOME IN THE ERA OF NOVEL P2Y12 INHIBITORS IN REAL-LIFE PATIENTS WITH ACUTE CORONARY SYNDROME: INSIGHTS FROM THE GREEK ANTIPLATELET (GRAPE) REGISTRY

Abstract

Few data exist on bivalirudin's clinical safety and efficacy in the context of contemporary antiplatelet treatment. We monitored in-hospital and 30-day bleeding events (Bleeding Academic Research Consortium -BARC classification) and major adverse cardiovascular events (MACEs) in the context of a